Axovant reaps the rewards from its gene therapy refocus
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Not developing your gene therapy? Call Axovant
Axovant's need to rebuild its pipeline is benefiting gene therapy developers.
Axovant looks to Oxford Biomedica for gene therapy resurrection
Axovant transforms itself into a new gene therapy company with an old Oxford Biomedica product.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.